![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Cyclic sulfur compounds targeting macrophage polarization into M2/protumor phenotype and their anti-tumor effects
Tumor-associated macrophages (TAMs), especially the M2-like phenotype, promote tumor progression, making them candidate targets for anti-tumor therapy. We previously discovered a cyclic sulfur compound, Onioni...
-
Article
CD163-positive cancer cells are potentially associated with high malignant potential in clear cell renal cell carcinoma
CD163 is preferentially expressed by monocyte/macrophages; however, recent studies using immunohistochemistry (IHC) have reported that some cancer cells also express CD163. In the present IHC study, we investi...
-
Article
Open AccessOnionin A inhibits ovarian cancer progression by suppressing cancer cell proliferation and the protumour function of macrophages
It is well known that tumour-associated macrophages (TAMs) play an important role in tumour development by modulating the tumour microenvironment, and targeting of protumour activation or the M2 polarization o...
-
Article
Chronic inflammation with Helicobacter pylori infection is implicated in CD44 overexpression through miR-328 suppression in the gastric mucosa
Infection with Helicobacter pylori is the main risk factor for development of gastric cancer. CD44 overexpression, especially that of variant 9 (CD44v9), has also been implicated in the local inflammatory respons...
-
Article
Hepatic Stellate Cells Accelerate the Malignant Behavior of Cholangiocarcinoma Cells
Although tumor–stromal interaction has been discussed, the role of hepatic stellate (HS) cells against cancer, especially cholangiocarcinoma (CC), has not been clarified. The aim of this study is to investigat...
-
Article
Intrahepatic dissemination of hepatocellular carcinoma after local ablation therapy
We aimed to clarify the histological features of and risk factors for intrahepatic dissemination after local ablation therapy (LAT) for hepatocellular carcinoma (HCC).